Login / Signup

Thymomatous myasthenia gravis: 10-year experience of a single center.

Jiaxin ChenWenjin ShangYin ChenYan LiXin HuangChunhua SuKai ZhuJieni ZhangWeibin LiuHuiyu Feng
Published in: Acta neurologica Scandinavica (2020)
T-MG is clinically different from NT-MG, and thymoma is considered a risk factor for MG. Preoperative anticholinesterase drug use is a protective factor for long-term prognosis of T-MG. A comprehensive understanding of the characteristics of T-MG will likely help improve its prognosis.
Keyphrases
  • myasthenia gravis
  • patients undergoing